Four-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Continued Improvement Across All Endpoints
09/02/2012
Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the …
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium 09/02/2012
Protalix BioTherapeutics, Inc. announced today that new clinical data on taliglucerase alfa will be presented at …
The EGA is pleased to announce that it received today from the EMA (European Medicines Agency) the confirmation that it complies with the criteria to be involved in the Agency’s activities. For more information...
Dear Friends
I would like to thank you all who attended the first regional meeting of Gaucher patients, on 5th November 2011, in Čatež, Slovenia. I would also like to thank the colleagues from Genzyme for logistical and financial support.
More …
The European Gaucher Alliance (EGA) is delighted to announce the launch of our new website resource. The new site contains a wealth of information on the work of the EGA and holds informative profiles of each member country association.
This launch …